# JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

> **NCT04280341** · PHASE1 · UNKNOWN · sponsor: **Peking University** · enrollment: 50 (estimated)

## Conditions studied

- HER2-Positive Solid Tumors

## Interventions

- **BIOLOGICAL:** RC48-ADC in combinaton with JS001

## Key facts

- **NCT ID:** NCT04280341
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-03
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04280341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04280341, "JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04280341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*